Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

101.43 -2.39 (-2.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
41 42 Next >
Investors Seek Second Act with Moderna Stock
MRNA stock struck gold with its Covid-19 vaccine but investors want to know if there are any other blockbusters in its pipeline. 
Via InvestorPlace
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
Via Benzinga
Ten Healthcare Companies With High Payout Ratio
The healthcare industry is among the biggest U.S. market segments in terms of market capitalization, but when it comes to dividend payouts, they rank very low. 
Via Talk Markets
10 Biggest Price Target Changes For Monday
Wells Fargo cut the price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $70 to $63. Gilead Sciences shares rose 0.4% to $59.91 in pre-market trading. 
Via Benzinga
What Cramer Thinks About Hims & Hers Health, Gilead Sciences And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Healthcare Realty Trust Incorporated (NYSE: HR) as the company’s merger with Healthcare Trust of America, Inc. 
Via Benzinga
High Dividend 50: Gilead Sciences
Gilead is offering an all-time high dividend yield of 5.0% and is trading at a forward price-to-earnings ratio of 9.1. Unfortunately, there are good reasons behind these seemingly attractive features... 
Via Talk Markets
Buy These 3 High-Yield Stocks If You're In Your 50s And Cruise Into Retirement
In your 50s and looking for age-appropriate investments? Fancy yourself some hefty income in lieu of big growth as you age? Want to glide into retirement and land on a sheet of big, safe, totally... 
Via Talk Markets
Todos Medical Acquires Lucrative NLC Assets For Pennies On The Dollar
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Moderna Rockets As It Attempts The Impossible: Vaccinating Against HIV
It hasn't been possible to vaccinate against HIV. Does Moderna stand a chance? 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.58% on an annualized basis. Buying $100 In GILD: 20 years ago, an investor could have... 
Via Benzinga
Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint
Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic... 
Via Benzinga
How A Mixed Breast Cancer Study Cast Doubt On Gilead's Immunomedics Buyout
Gilead's Trodelvy had mixed test results in patients with breast cancer. 
Via Investor's Business Daily
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
Gilead Hit By FDA Complete Response Letter For Lenacapavir In HIV Infection
The FDA has issued a complete response letter (CRL) for Gilead Sciences Inc's (NASDAQ: GILD) application for lenacapavir for heavily treated multi-drug... 
Via Benzinga
Where Gilead Sciences Stands With Analysts
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Tumble Following New Sanctions Against Russia
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones surged more than 800 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the... 
Via Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature. 
Via InvestorPlace
Is Moderna the Next Gilead or the Next Regeneron?
MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed. 
Via InvestorPlace
"Prudent" Biotech Bets
Here, we review two recommended biotechnology stocks following the release of their latest earnings reports. Let's take a look. 
Via Talk Markets
See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization
The FDA has revised the Emergency Use Authorization (EUA) for Merck & Co Inc's (NYSE: MRK) COVID-19 pill molnupiravir, explaining that it should be... 
Via Benzinga
Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients
Gilead Sciences Inc (NASDAQ: GILD) announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir in heavily pretreated multi-drug... 
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
Hookipa Pharma Stock Surges On HIV Pact With Gilead
Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral... 
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
Revisiting the Biggest Winners and Losers Since the COVID Crash Low
A look at how the average stock that’s currently in the S&P 1500 has done since the Covid crash low by sector. 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.